For instance, TCL1A-expressing B cells have been linked to oral squamous cell carcinoma, distinct B cell subsets have been identified in nasopharyngeal carcinoma, an interferon-stimulated B cell subtype has been associated with muscle-invasive bladder cancer, and CD20+CD22+ADAM28+ ICI-responsive B cells have also been characterized (70–73). Here, CD22 is linked to oral cavity squamous cell carcinoma.